Could Galectin Therapeutics Inc (NASDAQ:GALT) Skyrocket? The Stock Has Too Many Sellers

Galectin Therapeutics, Inc. (NASDAQ:GALT) Logo

Investors sentiment decreased to 1.54 in 2019 Q2. Its down 0.61, from 2.15 in 2019Q1. It dived, as 12 investors sold Galectin Therapeutics, Inc. shares while 12 reduced holdings. 23 funds opened positions while 14 raised stakes. 7.44 million shares or 18.92% more from 6.26 million shares in 2019Q1 were reported.
Fmr Ltd Liability invested 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT). The Ohio-based Fifth Third Bank has invested 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Stratos Wealth Partners Limited holds 41,450 shares or 0.01% of its portfolio. American Group Incorporated holds 0% or 20,506 shares. Charles Schwab Invest Mngmt Incorporated accumulated 0% or 75,092 shares. The Switzerland-based Credit Suisse Ag has invested 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Wells Fargo & Com Mn holds 0% or 6,734 shares. Barclays Public Ltd Liability invested 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT). California Employees Retirement invested in 23,450 shares or 0% of the stock. Northern reported 134,116 shares. 167 are held by Salem Invest Counselors. Moreover, Bankshares Of Montreal Can has 0% invested in Galectin Therapeutics, Inc. (NASDAQ:GALT). Jpmorgan Chase invested in 10,136 shares or 0% of the stock. Ameritas Inv Incorporated has 2,845 shares for 0% of their portfolio. Gp One Trading L P reported 15,562 shares.

Since May 29, 2019, it had 7 insider purchases, and 1 sale for $20.17 million activity. LEWIS JOEL bought $54,994 worth of stock or 12,849 shares. 18,578 Galectin Therapeutics, Inc. (NASDAQ:GALT) shares with value of $79,514 were bought by OMENN GILBERT S. Shares for $4,786 were bought by FREEMAN KEVIN D. $20.03 million worth of stock was bought by Uihlein Richard E on Wednesday, May 29. The insider ELDRED KARY bought 3,033 shares worth $12,981. 10X Fund – L.P. also sold $63,325 worth of Galectin Therapeutics, Inc. (NASDAQ:GALT) on Friday, August 2.

The stock of Galectin Therapeutics Inc (NASDAQ:GALT) registered an increase of 2.23% in short interest. GALT’s total short interest was 3.80 million shares in November as published by FINRA. Its up 2.23% from 3.71M shares, reported previously. With 408,100 shares average volume, it will take short sellers 9 days to cover their GALT’s short positions. The short interest to Galectin Therapeutics Inc’s float is 11.04%.

The stock increased 0.50% or $0.02 during the last trading session, reaching $4. About 80,607 shares traded. Galectin Therapeutics, Inc. (NASDAQ:GALT) has declined 25.70% since November 2, 2018 and is downtrending. It has underperformed by 25.70% the S&P500.

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company has market cap of $227.14 million. The companyÂ’s lead product candidate includes galectin-3 inhibitor , a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It currently has negative earnings. It also engages in developing GM-CT-01, which is in pre-clinical development state for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis.

More notable recent Galectin Therapeutics, Inc. (NASDAQ:GALT) news were published by: Globenewswire.com which released: “Galectin Therapeutics Raises $44.5 Million in Rights Offering and $2.5 Million from Warrant Exercise – GlobeNewswire” on May 28, 2019, also Globenewswire.com with their article: “Providence Cancer Institute to Present Findings on GR-MD-02 at the 2019 Keystone Symposia on Molecular and Cellular Biology – GlobeNewswire” published on March 22, 2019, Benzinga.com published: “Stocks That Hit 52-Week Lows On Friday – Benzinga” on August 23, 2019. More interesting news about Galectin Therapeutics, Inc. (NASDAQ:GALT) were released by: Benzinga.com and their article: “30 Stocks Moving In Tuesday’s Pre-Market Session – Benzinga” published on June 18, 2019 as well as Fool.com‘s news article titled: “2 Clinical-Stage Biotech Stocks That Could Soar Next Week – The Motley Fool” with publication date: June 17, 2018.

Galectin Therapeutics, Inc. (NASDAQ:GALT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.